Vynleads (VYND) 10-K 31 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	333-227499
Entity Registrant Name	Vynleads, Inc.
Entity Central Index Key	0001745078
Entity Tax Identification Number	47-4584272
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	596 Herrons Ferry Road
Entity Address, Address Line Two	Suite 301
Entity Address, City or Town	Rock Hill
Entity Address, State or Province	SC
Entity Address, Postal Zip Code	29730
City Area Code	(845)
Local Phone Number	745-0981
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		11,599,830
Auditor Firm ID	287
Auditor Name	Liggett & Webb, P.A.
Auditor Location	Boynton Beach, Florida

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 1,716	$ 7,229
Accounts Receivable		635
Holdback Receivable from merchant, net of reserve for refunds of $58 and $42, respectively	15,764	16,929
Prepaid Expenses and other current assets	7,910	13,206
Total current assets	25,390	37,999
Total assets	25,390	37,999
Current Liabilities:
Accounts payable and accrued expenses	267,006	256,784
Notes Payable	235,250	122,575
Notes Payable – Related Party	15,000
Total current liabilities	517,256	379,359
Notes Payable, net of current		8,925
Total liabilities	517,256	388,284
Commitments and contingencies (See Note 8)
Stockholders' deficit:
Preferred stock; $0.0001 par value; 5,000,000 shares authorized, no shares issued and outstanding, respectively
Common stock; $0.0001 par value; 50,000,000 shares authorized; 11,599,830 shares and 11,599,830 shares issued and outstanding, respectively	1,160	1,160
Additional paid-in capital	1,494,252	1,364,252
Accumulated deficit	(1,987,278)	(1,715,697)
Total stockholders' deficit	(491,866)	(350,285)
Total liabilities and stockholders' deficit	$ 25,390	$ 37,999

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Refunds	$ 58	$ 42
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	11,599,830	11,599,830
Common stock, shares issued	11,599,830	11,599,830

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue, net of refunds and chargebacks	$ 484	$ 48,262
Cost and Expenses:
Cost of Revenue	32,467	56,708
Advertising		895
Selling, general and administrative expense	234,790	362,947
Total costs and expenses	267,257	420,550
Loss from operations	(266,773)	(372,288)
Other income	6,250	2,000
Interest expense	(11,058)	(8,188)
Net loss before provision for income taxes	(271,581)	(378,476)
Income tax expense		(1,154)
Net loss	$ (271,581)	$ (379,630)
Net loss per common share, basic and diluted	$ (0.02)	$ (0.03)
Weighted average common shares outstanding, basic and diluted	11,596,431	11,469,717

Statements of Stockholders' Def

Statements of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 1,140	$ 1,199,565	$ (1,336,067)	$ (135,362)
Beginning balance, shares at Dec. 31, 2019	11,399,830
Common Stock Issued for Services	$ 20	44,980		45,000
Common Stock Issued for Services, shares	200,000
Stock-based compensation		224		224
Capital Contribution		119,483		119,483
Net Loss			(379,630)	(379,630)
Ending balance, value at Dec. 31, 2020	$ 1,160	1,364,252	(1,715,697)	(350,285)
Ending balance, shares at Dec. 31, 2020	11,599,830
Capital Contribution		130,000		130,000
Net Loss			(271,581)	(271,581)
Ending balance, value at Dec. 31, 2021	$ 1,160	$ 1,494,252	$ (1,987,278)	$ (491,866)
Ending balance, shares at Dec. 31, 2021	11,599,830

Statement of Cash Flows

Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (271,581)	$ (379,630)
Adjustments to reconcile net loss to net cash flows used in operating activities
Stock-based compensation		39,599
Capital contribution from CEO	130,000	119,483
PPP Courtesy Credit	(6,250)
Changes in operating assets and liabilities and other, net	17,318	107,882
Net cash flows used in operating activities	(130,513)	(112,666)
Cash flows from financing activities:
Proceeds from notes payable	120,000	56,500
Proceeds from notes payable – related party	15,000
Repayment of notes payable	(10,000)
Net cash flows provided by financing activities	125,000	56,500
Net decrease in cash	(5,513)	(56,166)
Cash at beginning of year	7,229	63,395
Cash at end of year	1,176	7,229
Supplemental disclosure of cash flow information:
Income taxes paid		1,555
Interest paid	3,226	5,602
Supplemental for non-cash investing and financing activities:
Stock issued for prepaid consulting		$ 5,625

Business

Business	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	1. Business Vynleads, Inc. (“Vynleads”) was incorporated as a Delaware corporation on July 15, 2015. We are a provider of health and wellness information principally targeted to people who are pre-diabetes or who have type 2 diabetes. We provide information to our customers who are seeking to make healthy choices by providing clear, generic blueprints, education, resources, and support. Our core product is our proprietary Lifestyle Blueprint, a digital guide that provides dietary recommendations for a very low calorie eight-week diet together with information focusing on what, how and how much a person eats, nutritional information and how a person’s body does and does not use food to enable our customers to continue leading a more successful lifestyle. We also offer nutritional supplements and monthly subscriptions to our proprietary newsletter which covers a wide variety of healthy living-related topics. Our corporate headquarters are located in Rock Hill, South Carolina.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. Going Concern Our financial statements have been presented on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since July 15, 2015, the date of our inception, we have experienced recurring operating losses and negative operating cash flows, and have financed our recent working capital requirements primarily through the issuance of debt. During the years ended December 31, 2021 and 2020, we have reported net losses of $ 271,581 379,630 491,866 1,987,278 130,513 Despite our current sales, expense, cash flow projections, and aggregate cash and holdback receivable from our merchant, net of reserve for refunds, of $ 15,764 Our ability to meet our current and projected obligations depends on our ability to generate sufficient sales and to control expenses and will require that we seek additional capital through private and/or public financing sources. There can be no assurances that we will achieve our forecasted financial results or that we will be able to raise additional capital to operate our business. Any such failure would have a material adverse impact on our liquidity and financial condition and could force us to curtail or discontinue operations entirely and could require us to file for protection under bankruptcy laws. These conditions raise substantial doubt as to our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome from this uncertainty.

Summary of Critical Accounting

Summary of Critical Accounting Policies	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Critical Accounting Policies	3. Summary of Critical Accounting Policies Accounting Principles The financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining our reserve for refunds, our holdback reserve, and valuation of stock-based compensation. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements. Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value. Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for returns, which reserve is $ 58 42 Revenue Recognition The Company accounts for revenue in accordance with Accounting Standard Codification (“ASC”) Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for years ended December 31, 2021 and 2020 are as follows: Percentage of Revenue by Type Year ended December 31, 2021 2020 Internet content subscriptions 0.0 % 15.2 % Nutritional supplements 100.0 % 84.8 % Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue. Advertising Costs Advertising costs for the years ended December 31, 2021 and 2020 were $ 0 895 Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766 Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense. Stock-Based Compensation We account for stock based instruments issued to employees and non-employees for services in accordance with Accounting Standard Codification (“ASC”) Topic 718. Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value. The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends Expected Volatility Risk-Free Interest Rate Expected Term Grant Date Price of Common Stock Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820- 10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity. The carrying amounts of our cash, holdback receivable, prepaid expense and other current asset, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of December 31, 2021 and 2020. Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that, other than the following, they are either immaterial or not relevant to us.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $ 15,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 596 During the year ended December 31, 2021 and 2020, we paid to Mr. Bezusov $ 0 2,000 On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. Mr. Mannine’s compensation includes a grant of 10 100,000 0.225 During the year ended December 31, 2020, Mr. Mannine personally paid $ 3,040 On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. During the years ended December 31, 2021 and 2020, $ 130,000 116,443 On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2020, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed until May 2022. As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including: · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	5. Income Taxes For the year ended December 31, 2021, the provision for income taxes was $ 0 1,154 As of December 31, 2 021 h a a 1.8 O n r n e h u z n a e Net operating losses of approximately $407,000 will begin expiring in 2037. Income taxes amounted to less than the amounts computed by applying the U.S. Federal income tax rate of 21% to income (loss) before income taxes. Income Tax Rate Reconciliation 2021 2020 Tax Rate Tax Rate Taxes computed at statutory rate Federal $ (57,032 ) 21.00 % $ (79,480 ) 21.00 % State (10,727 ) 3.95 % (14,950 ) 3.95 % Total taxes at blended statutory rate $ (67,759 ) 24.95 % $ (94,430 ) 24.95 % Increase (decrease) resulting from: Effect of tax rate change — 0.00 % — 0.00 % Nondeductible expenses — 0.00 % — 0.00 % State income tax refund — 0.00 % — 0.00 % Other 385 -0.14 % 3,318 -0.88 % Change in valuation allowance 67,374 -24.81 % 92,266 -24.38 % Total income tax (benefit) expense $ — -0.00 % $ 1,154 -0.31 % Deferred Tax Assets and Liabilities 2021 2020 Deferred tax assets: Net operating loss carryforward $ 509,708 $ 441,506 Amortization of intangibles 7,485 8,317 Reserve for refunds 15 11 Stock compensation 3,774 774 Charitable contribution carryforward 3,355 3,355 Total deferred tax assets 524,337 456,963 Less: Valuation allowance (524,337 ) (456,963 ) Net deferred tax assets $ — $ — In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Because of our historical earnings history, the net deferred tax asset for 2021 has been reduced based on the amount deemed recoverable from the use of loss carrybacks. The change in the valuation allowance was an increase of $ 67,374 92,266

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable On December 1, 2021, the Company executed a note payable to an individual in the amount of $ 15,000 5 due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 62 On September 28, 2021, the Company executed a note payable to an individual in the amount of $ 50,000 5 due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 644 On August 4, 2021, the Company executed a note payable to an individual in the amount of $ 15,000 , interest accrues at 5 % per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 306 On May 10, 2021, the Company executed a note payable to an individual in the amount of $ 20,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 644 On April 15, 2021, the Company executed a note payable to an individual in the amount of $ 10,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 356 On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $ 15,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 596 On February 3, 2021, the Company executed a note payable to an individual in the amount of $ 10,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 400 On December 17, 2020, the Company executed a note payable to an individual in the amount of $ 19,500 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 1,015 40 On October 27, 2020, the Company executed a note payable to an individual in the amount of $ 10,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 590 90 On May 5, 2020, the Company received loan proceeds in the amount of $ 27,000 The loan matures on April 20, 2022 and bears an interest rate of 1.00 6,250 20,750 3,433 On November 18, 2019, the Company executed a note payable to an individual in the amount of $ 50,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 1,250 4,010 1,510 On November 18, 2019, the Company executed a note payable to an individual in the amount of $ 25,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 2,630 1,380

Economic Injury Disaster Loan

Economic Injury Disaster Loan	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Economic Injury Disaster Loan	7. Economic Injury Disaster Loan On April 14, 2020, the Company received a grant in the amount of $ 2,000

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Employment Agreement On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. The initial term of the agreement expires in June 2023, subject to successive automatic one- year renewals unless a non-renewal notice is received by either party at least 90 days prior to the expiration of the then current renewal term. Mr. Mannine’s compensation includes: · an annual base salary of $ 130,000 · an annual bonus as determined by the board of directors; · a grant of 10 100,000 0.225 · participation in all benefit plans we may offer our employees; and · 20 paid vacation days annually. Mr. Mannine's employment agreement may be terminated, and he is entitled to certain payments upon such termination, as follows: · if we should terminate Mr. Mannine’s employment without “cause” or if he should resign for “good reason" or if a “change of control” occurs, we are obligated to pay him a lump-sum severance payment equal to the sum of three months’ base salary, plus one month for every year he was employed and 50% of three years annual bonus (based on the prior year’s compensation); · if Mr. Mannine’s employment is terminated as a result of his death or disability, he is entitled to receive his base salary and a pro-rata annual bonus, if any, based on the year during which such termination is effective; or · if we should terminate Mr. Mannine for “cause,” or if he voluntarily terminates the agreement, he is entitled to receive his base salary only through the date of termination, and he is not be entitled to any other compensation for the calendar year during which the termination occurs or any subsequent calendar period, including, but not limited to, any annual bonus, if any, that has not already been paid. The employment agreement with Mr. Mannine contains customary confidentiality, non-compete and indemnification clauses. On September 21, 2020, Mr. Mannine agreed to voluntarily cancel the employment agreement. During the years ended December 31, 2021 and 2020, Mr. Mannine voluntarily agreed to waive all cash due and any related accruals. The salary forgiven for the years ended December 31, 2021 and 2020 of 130,000 116,443 Co mm tments On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2019, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed until May 2022. · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions. On February 12, 2020, we entered a consulting agreement with Primoris Group Inc (“Primoris”). Primoris was issued 200,000 45,000 0.225 100,000 0 3,937 0 5,625 Under terms of the consulting agreement, we agree to pay Primoris $ 8,000 96,000 84,000 Contingencies In April 2016, we entered into a Promotion and Royalty Agreement (the “Agreement”) with a consultant to obtain certain promotional services from him (the “Promoter”), including the use of his name and appearance. In consideration for the services rendered by the Promoter, we agreed to use commercially reasonable efforts to promote and sell a book authored by him (the “Book”) and to pay him a percentage of the sales of the Book after deductions for all direct costs of fulfilling such sales (the “Royalty”). During the course of 2017, the Promoter initiated a series of informal claims and filed unauthorized uniform commercial code financing statements (“UCC Liens”) in several states as liens against us and certain of our officers, directors, and founders, alleging non- payment for the Royalty amounts due under the Agreement. We dispute the Promoter’s claims and have determined that any and all amounts due to the Promoter under the Agreement have been paid in full. We have succeeded in removing certain of the UCC Liens and are pursuing action to remove the remaining unauthorized UCC Liens. We do not believe that the claims of the Promoter are valid in any respect.

Concentration of Credit Risk an

Concentration of Credit Risk and Major Customers and Suppliers	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Concentration of Credit Risk and Major Customers and Suppliers	9. Concentration of Credit Risk and Major Customers and Suppliers None of our revenues are concentrated with any single customer composing 10% or more of our total revenues. We purchase our inventory of herbal/natural supplements from one supplier. While we believe that we will be able to find a secondary supplier, there could be a manufacturing delay in the transition to a new supplier and such a supply interruption would materially impact our business for some period of time.

Stockholders Deficit

Stockholders Deficit	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders Deficit	10. Stockholders Deficit Our authorized capital stock consists of 50,000,000 0.0001 5,000,000 0.0001 11,599,830 11,599,830 no Contributed Capital On September 21, 2020, Mr. Mannine voluntarily agreed to cancel his employment agreement and waive all cash due and any related accruals. The salary forgiven for the year ended December 31, 2021 and 2020 of 130,000 116,443 treated as in-kind contribution of service and reflected as contributed capital in the financial statements (See notes 4 and 8). During the year ended December 31, 2020, Mr. Mannine personally paid $ 3,040 Consulting Agreement On February 12, 2020, we entered a consulting agreement with Primoris Group Inc (“Primoris”). Primoris was issued 200,000 common shares at a fair value of $ 45,000 ($ 0.225 per share) on June 30, 2020. 100,000 shares are restricted from resale or transfer by Primoris per the consulting agreement until February 12, 2021. The consultant has an option to register 100,000 on any future registration statement. In addition to any restrictions imposed by the agreement, all the shares require an exemption for resale to the public. The agreement was not renewed upon expiration date. Preferred Stock Our board of directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and other matters. Our board of directors may authorize the issuance of preferred stock, which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our board of directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of our common stock to be effective while any shares of preferred stock are outstanding. Warrants O Oct o e 1 0 2017 w entere h F n n i t C G a mor full esc ibe i Not 4 and 8 In connection with the related equity financing as of December 31, 2017, CRG had earned 368,111 0.225 34,405 0.225 45 2.2 5 During January 2018, as part of the Private Placement more fully described in Note 4, CRG earned an additional 17,655 0.225 1,670 0.225 45 2.51 5 On March 8, 2018, we entered into an advisory agreement with a scientific advisor to provide certain services to us. Pursuant to the agreement, we issued 100,000 0.90 100,000 100,000 1,905 0.225 45 2.63 5 During the years ended December 31, 2021 and 2020, we have recorded stock-based compensation expense of $ 0 224 As of December 31, 2021 and December 31, 2020, the intrinsic value for warrants outstanding and exercisable is $ 28,932 144,662 The following table summarizes information about the warrants outstanding and exercisable as of December 31, 2021 and 2020: Warrants outstanding and exercisable 2021 2020 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding, beginning of year 485,766 $ 0.364 485,766 $ 0.364 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of year 485,766 $ 0.364 485,766 $ 0.364 Exercisable, end of year 485,766 $ 0.364 485,766 $ 0.364 As of December 31, 2021 Warrants outstanding and exercisable by range of exercise price Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.225 0.90 485,766 1.10 $ 0.364 485,766 $ 0.364 As of December 31, 2020 Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.225 0.90 485,766 2.10 $ 0.364 485,766 $ 0.364

Stock Option Plan

Stock Option Plan	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock Option Plan	11. Stock Option Plan In December 2017 our board of directors adopted our 2017 Equity Incentive Plan, or the “2017 Plan.” Our stockholders ratified the 2017 Plan in December 2017. The purpose of the 2017 Plan is to encourage ownership in our company by our officers, directors, employees and consultants, and to incentivize and align the interests of the plan participants with the interests of our stockholders. We have reserved 1,100,000 The board of directors or a committee of the board of directors administers the 2017 Plan. Presently, the 2017 Plan is administered by our board of directors. The term of each plan option and the manner in which it may be exercised is determined by the board of directors or a committee of the board of directors, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant. The terms of grants or any other type of award under the plan are determined by the board of directors or committee of the board of directors at the time of grant. The 2017 Plan provides that the maximum value of any award during any calendar year cannot exceed $1,000,000. Any option granted under the plan must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant, but the exercise price of any ISO granted under the 2017 Plan to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The 2017 Plan further provides that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any plan participant during any calendar year cannot exceed $100,000. Option awards may provide for the exercise by means of cash, consideration received by us under a broker-assisted sale and remittance program, cashless exercise, any other consideration legally permitted, or a combination of the foregoing. The 2017 Plan administrator may also determine the method of payment of the exercise price at the time the option is being exercised. Grants under the 2017 Plan are not transferrable. Generally, options which are exercisable at the date of the plan participant’s termination from our employment or severance of the relationship with our company must be exercised within three months of the termination date; the plan administrator may extend the exercise period of the option for a separated plan participant providing that the extended date does not go beyond the original expiration date of the option. Similarly, generally options which are exercisable at the date of the plan participant’s disability or death must be exercised within six months of the termination date in the event of the disability of the plan participant or 12 months following the plan participant’s death. In our discretion, any outstanding options held by a plan participant terminated for cause may be immediately cancelled. In the event there is a “change in control” of our company as defined in the 2017 Plan, as determined by the board of directors or the committee, we may in our discretion: i) provide for the assumption or substitution of, or adjustment (including to the number and type of shares and exercise or purchase price applicable) to, each outstanding award; ii) accelerate the vesting of options and terminate any restrictions on stock awards; and/or iii) provide for termination of awards as a result of the change in control on such terms and conditions as it deems appropriate, including providing for the cancellation of awards for a cash or other payment to the participant. The number of shares of our common stock underlying any outstanding but unexercised option and the exercise price of that option will be proportionally adjusted in the event of a stock split, stock combinations, dividends, and similar corporate events. On June 14, 2018, pursuant to the employment agreement with Mr. Mannine, more fully described in Note 8, we issued 100,000 0.225 13,221 45 2.2 10 As of December 31, 2021 and December 31, 2020, the intrinsic value for option outstanding and exercisable is $ 7,500 37,500 The following table summarizes information about stock options outstanding and exercisable as of as of December 31, 2021 and 2020: Options outstanding and exercisable 2021 2020 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Outstanding, beginning of year 100,000 $ 0.225 100,000 $ 0.225 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of year 100,000 $ 0.225 100,000 $ 0.225 Exercisable, end of year 100,000 $ 0.225 100,000 $ 0.225 Options available for future grant, end of year 1,000,000 1,000,000 As of December 31, 2021 Options outstanding by exercise price range Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.225 100,000 6.93 $ 0.225 100,000 $ 0.225 As of December 31, 2020 Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.225 100,000 7.93 $ 0.225 100,000 $ 0.225

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On January 26, 2022, the Company executed a note payable to an individual in the amount of $ 20,000 5 due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. On February 10, 2022, the Company executed a note payable to an individual in the amount of $ 20,000 5 due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Summary of Critical Accountin_2

Summary of Critical Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Principles	Accounting Principles The financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).
Use of Accounting Estimates	Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining our reserve for refunds, our holdback reserve, and valuation of stock-based compensation. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements.
Cash	Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value.
Holdback Receivable	Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for returns, which reserve is $ 58 42
Revenue Recognition	Revenue Recognition The Company accounts for revenue in accordance with Accounting Standard Codification (“ASC”) Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for years ended December 31, 2021 and 2020 are as follows: Percentage of Revenue by Type Year ended December 31, 2021 2020 Internet content subscriptions 0.0 % 15.2 % Nutritional supplements 100.0 % 84.8 %
Shipping and Handling Costs	Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue.
Advertising Costs	Advertising Costs Advertising costs for the years ended December 31, 2021 and 2020 were $ 0 895
Loss Per Share	Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766
Income Taxes	Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense.
Stock-Based Compensation	Stock-Based Compensation We account for stock based instruments issued to employees and non-employees for services in accordance with Accounting Standard Codification (“ASC”) Topic 718. Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value. The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends Expected Volatility Risk-Free Interest Rate Expected Term Grant Date Price of Common Stock
Fair Value of Financial Instruments	Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820- 10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity. The carrying amounts of our cash, holdback receivable, prepaid expense and other current asset, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of December 31, 2021 and 2020.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that, other than the following, they are either immaterial or not relevant to us.

Summary of Critical Accountin_3

Summary of Critical Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Percentage of Revenue by Type	Percentage of Revenue by Type Year ended December 31, 2021 2020 Internet content subscriptions 0.0 % 15.2 % Nutritional supplements 100.0 % 84.8 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Tax Rate Reconciliation	Income Tax Rate Reconciliation 2021 2020 Tax Rate Tax Rate Taxes computed at statutory rate Federal $ (57,032 ) 21.00 % $ (79,480 ) 21.00 % State (10,727 ) 3.95 % (14,950 ) 3.95 % Total taxes at blended statutory rate $ (67,759 ) 24.95 % $ (94,430 ) 24.95 % Increase (decrease) resulting from: Effect of tax rate change — 0.00 % — 0.00 % Nondeductible expenses — 0.00 % — 0.00 % State income tax refund — 0.00 % — 0.00 % Other 385 -0.14 % 3,318 -0.88 % Change in valuation allowance 67,374 -24.81 % 92,266 -24.38 % Total income tax (benefit) expense $ — -0.00 % $ 1,154 -0.31 %
Deferred Tax Assets and Liabilities	Deferred Tax Assets and Liabilities 2021 2020 Deferred tax assets: Net operating loss carryforward $ 509,708 $ 441,506 Amortization of intangibles 7,485 8,317 Reserve for refunds 15 11 Stock compensation 3,774 774 Charitable contribution carryforward 3,355 3,355 Total deferred tax assets 524,337 456,963 Less: Valuation allowance (524,337 ) (456,963 ) Net deferred tax assets $ — $ —

Stockholders Deficit (Tables)

Stockholders Deficit (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Warrants outstanding and exercisable	Warrants outstanding and exercisable 2021 2020 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding, beginning of year 485,766 $ 0.364 485,766 $ 0.364 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of year 485,766 $ 0.364 485,766 $ 0.364 Exercisable, end of year 485,766 $ 0.364 485,766 $ 0.364
Warrants outstanding and exercisable by range of exercise price	Warrants outstanding and exercisable by range of exercise price Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.225 0.90 485,766 1.10 $ 0.364 485,766 $ 0.364 As of December 31, 2020 Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.225 0.90 485,766 2.10 $ 0.364 485,766 $ 0.364

Stock Option Plan (Tables)

Stock Option Plan (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Options outstanding and exercisable	Options outstanding and exercisable 2021 2020 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Outstanding, beginning of year 100,000 $ 0.225 100,000 $ 0.225 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of year 100,000 $ 0.225 100,000 $ 0.225 Exercisable, end of year 100,000 $ 0.225 100,000 $ 0.225 Options available for future grant, end of year 1,000,000 1,000,000
Options outstanding by exercise price range	Options outstanding by exercise price range Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.225 100,000 6.93 $ 0.225 100,000 $ 0.225 As of December 31, 2020 Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.225 100,000 7.93 $ 0.225 100,000 $ 0.225

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 271,581	$ 379,630
Working capital deficit	491,866
Accumulated deficit	1,987,278	1,715,697
Net cash used in operations	130,513	112,666
Holdback Receivable from merchant, net of reserve for refunds	$ 15,764	$ 16,929

Summary of Critical Accountin_4

Summary of Critical Accounting Policies (Details) - Revenue, Product and Service Benchmark [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Internet Content Subscriptions [Member]
Product Information [Line Items]
Percentage of revenues	0.00%	15.20%
Nutritional Supplements [Member]
Product Information [Line Items]
Percentage of revenues	100.00%	84.80%

Summary of Critical Accountin_5

Summary of Critical Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Refunds	$ 58	$ 42
Advertising	$ 0	$ 895
Potentially dilutive shares	585,766	585,766

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 14, 2018	Mar. 16, 2021	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Options issued
Exercise price
In-kind Contribution of Service			$ 130,000	$ 116,443
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Consulting fees			0	2,000
Expected term	10 years
Options issued	100,000
Exercise price	$ 0.225
Expenses paid by CEO			3,040	$ 3,040
Note Payable [Member] | Mr Sergei Stetsenko [Member]
Related Party Transaction [Line Items]
Note payable		$ 15,000
Interest rate		5.00%
Term		due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Accrued interest			$ 596

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal	$ (57,032)	$ (79,480)
Federal	21.00%	21.00%
State	$ (10,727)	$ (14,950)
State	3.95%	3.95%
Total taxes at blended statutory rate	$ (67,759)	$ (94,430)
Total taxes at blended statutory rate	24.95%	24.95%
Effect of tax rate change
Effect of tax rate change	0.00%	0.00%
Nondeductible expenses
Nondeductible expenses	0.00%	0.00%
State income tax refund
State income tax refund	0.00%	0.00%
Other	$ 385	$ 3,318
Other	(0.14%)	(0.88%)
Change in valuation allowance	$ 67,374	$ 92,266
Change in valuation allowance	(24.81%)	(24.38%)
Total income tax (benefit) expense		$ 1,154
Total income tax (benefit) expense	(0.00%)	(0.31%)

Income Taxes (Details - Income

Income Taxes (Details - Income Tax Rate Reconciliation) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryforward	$ 509,708	$ 441,506
Amortization of intangibles	7,485	8,317
Reserve for refunds	15	11
Stock compensation	3,774	774
Charitable contribution carryforward	3,355	3,355
Total deferred tax assets	524,337	456,963
Less: Valuation allowance	(524,337)	(456,963)
Net deferred tax assets

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 1,154
Net operating loss carryforwards	$ 1,800,000
[custom:IncomeTaxesDescription]	Net operating losses of approximately $407,000 will begin expiring in 2037. Income taxes amounted to less than the amounts computed by applying the U.S. Federal income tax rate of 21% to income (loss) before income taxes.
Valuation allowance	$ 67,374	$ 92,266

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)

Dec. 01, 2021

Oct. 04, 2021

Sep. 15, 2021

Aug. 04, 2021

May 10, 2021

Apr. 15, 2021

Mar. 16, 2021

Feb. 03, 2021

Dec. 17, 2020

May 05, 2020

Nov. 18, 2019

Sep. 28, 2021

Oct. 27, 2020

Dec. 31, 2021

Dec. 31, 2020

Nov. 19, 2021

May 14, 2020

Short-term Debt [Line Items]

PPP Courtesy Credit

$ 6,250

$ 6,250

Note Payable One [Member]

Short-term Debt [Line Items]

Note payable

$ 15,000

Interest rate

5.00%

Term

due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

62

Note Payable Two [Member]

Short-term Debt [Line Items]

Note payable

$ 50,000

Interest rate

5.00%

Term

due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

644

Note Payable Three [Member]

Short-term Debt [Line Items]

Note payable

$ 15,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

$ 306

Note Payable Four [Member]

Short-term Debt [Line Items]

Note payable

$ 20,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

$ 644

Note Payable Five [Member]

Short-term Debt [Line Items]

Note payable

$ 10,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

$ 356

$ 596

Note Payable Six [Member]

Short-term Debt [Line Items]

Note payable

$ 15,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Note Payable Seven [Member]

Short-term Debt [Line Items]

Note payable

$ 10,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

$ 400

Note Payable Eight [Member]

Short-term Debt [Line Items]

Note payable

$ 19,500

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

1,015

40

Note Payable Nine [Member]

Short-term Debt [Line Items]

Note payable

$ 10,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

590

90

P P P Loan [Member]

Short-term Debt [Line Items]

Note payable

20,750

Interest rate

1.00%

Term

The loan matures on April 20, 2022 and bears an interest rate of 1.00%

Proceeds from Loans

$ 27,000

Debt Instrument, Periodic Payment

$ 3,433

Note Payable Ten [Member]

Short-term Debt [Line Items]

Note payable

$ 50,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

4,010

1,510

$ 1,250

Note Payable Eleven [Member]

Short-term Debt [Line Items]

Note payable

$ 25,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

$ 2,630

$ 1,380

Economic Injury Disaster Loan (

Economic Injury Disaster Loan (Details Narrative)	Apr. 14, 2020USD ($)
Other Income and Expenses [Abstract]
Other income	$ 2,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Jun. 30, 2020	Feb. 12, 2020	Jun. 14, 2018	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Options issued
Exercise price
Stock-based compensation				$ 0	$ 3,937
Prepaid expense				0	5,625
Primoris Group Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Issued		200,000
Fair value	$ 45,000	$ 45,000
Offering price		$ 0.225
Shares restricted		100,000
Consulting fee payable				8,000
Accrued expense				96,000	84,000
Chief Executive Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Annual base salary			$ 130,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			10 years
Options issued			100,000
Exercise price			$ 0.225
Capital contribution from CEO's salary				$ 130,000	$ 116,443

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Details - Information About Warrants Earned and Outstanding) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning of period	485,766	485,766
Outstanding, beginning of period	$ 0.364	$ 0.364
Granted
Granted
Exercised
Exercised
Forfeited
Forfeited
Expired
Expired
Outstanding, end of period	485,766	485,766
Outstanding, end of period	$ 0.364	$ 0.364
Exercisable, end of period	485,766	485,766
Exercisable, end of period	$ 0.364	$ 0.364

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details - Warrants Outstanding by Price Range) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	$ 0.225	$ 0.225
Range of exercise price, upper limit	$ 0.90	$ 0.90
Number outstanding	485,766	485,766
Remaining Average Contractual Life	1 year 1 month 6 days	2 years 1 month 6 days
Weighted Average Exercise Price, Outstanding	$ 0.364	$ 0.364
Number exercisable	485,766	485,766
Weighted average exercise price, exercisable	$ 0.364	$ 0.364

Stockholders Deficit (Details N

Stockholders Deficit (Details Narrative) - USD ($)	Jun. 30, 2020	Feb. 12, 2020	Jun. 14, 2018	Mar. 08, 2018	Oct. 10, 2017	Jan. 31, 2018	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized							50,000,000	50,000,000
Common stock, par value							$ 0.0001	$ 0.0001
Preferred stock, shares authorized							5,000,000	5,000,000
Preferred stock, par value							$ 0.0001	$ 0.0001
Common stock, shares outstanding							11,599,830	11,599,830
Preferred stock, share issued							0	0
Preferred stock, shares outstanding							0	0
Stock-based compensation							$ 0	$ 224
Intrinsic value for warrants outstanding							$ 28,932	144,662
Primoris Group Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues		200,000
Fair value	$ 45,000	$ 45,000
Offering price		$ 0.225
Issued		200,000
Primoris Group Inc [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested		100,000
C R G Finance A G [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value					$ 34,405	$ 1,670
Offering price					$ 0.225	$ 0.225
Issued					368,111	17,655
Exercise price					$ 0.225	$ 0.225
Volatility					45.00%	45.00%
Risk free interest rate					2.20%	2.51%
Expected life					5 years	5 years
Scientific Advisor [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value				$ 1,905
Offering price				$ 0.225
Vested							100,000
Issued				100,000
Exercise price				$ 0.90
Volatility				45.00%
Risk free interest rate				2.63%
Expected life				5 years
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Capital contribution from CEO's salary							$ 130,000	116,443
Expenses paid by CEO							$ 3,040	$ 3,040
Volatility			45.00%
Risk free interest rate			2.20%
Expected life			10 years

Stock Option Plan (Details - St

Stock Option Plan (Details - Stock Options Outstanding) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Outstanding, beginning of period	100,000	100,000
Outstanding, beginning of period	$ 0.225	$ 0.225
Granted
Granted
Exercised
Exercised
Forfeited
Forfeited
Expired
Expired
Outstanding, end of period	100,000	100,000
Outstanding, end of period	$ 0.225	$ 0.225
Exercisable, end of period	100,000	100,000
Exercisable	$ 0.225	$ 0.225
Options available for future grant	1,000,000	1,000,000

Stock Option Plan (Details - _2

Stock Option Plan (Details - Stock Options Outstanding by Exercise Price) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Range of Exercise Price, upper	$ 0.225	$ 0.225
Number Outstanding	100,000	100,000
Remaining Average Contractual Life	6 years 11 months 4 days	7 years 11 months 4 days
Weighted Average Exercise Price	$ 0.225	$ 0.225
Number Exercisable	100,000	100,000
Exercisable Weighted Average Exercise Price	$ 0.225	$ 0.225

Stock Option Plan (Details Narr

Stock Option Plan (Details Narrative) - USD ($)	Jun. 14, 2018	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Total awards reserved		1,100,000
Options issued
Exercise price
Intrinsic value		$ 7,500	$ 37,500
Chief Executive Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Options issued	100,000
Exercise price	$ 0.225
Options fair value	$ 13,221
Expected volatility	45.00%
Risk free rate	2.20%
Expected term	10 years

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 10, 2022	Dec. 01, 2021	Jan. 26, 2022	Sep. 28, 2021
Note Payable One [Member]
Subsequent Event [Line Items]
Note payable		$ 15,000
Interest rate		5.00%
Term		due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Note Payable Two [Member]
Subsequent Event [Line Items]
Note payable				$ 50,000
Interest rate				5.00%
Term				due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Subsequent Event [Member] | Note Payable One [Member]
Subsequent Event [Line Items]
Note payable			$ 20,000
Interest rate			5.00%
Term			due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Subsequent Event [Member] | Note Payable Two [Member]
Subsequent Event [Line Items]
Note payable	$ 20,000
Interest rate	5.00%
Term	due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.